Moleculin Biotech, Inc. (NASDAQ:MBRX) Sees Large Increase in Short Interest

Moleculin Biotech, Inc. (NASDAQ:MBRX) was the recipient of a large increase in short interest in the month of July. As of July 31st, there was short interest totaling 1,577,365 shares, an increase of 49.6% from the July 15th total of 1,054,620 shares. Based on an average daily volume of 1,913,836 shares, the short-interest ratio is presently 0.8 days. Currently, 22.5% of the company’s shares are short sold.

Moleculin Biotech Price Performance

Shares of NASDAQ:MBRX traded down $0.03 on Wednesday, hitting $0.58. 439,095 shares of the company’s stock were exchanged, compared to its average volume of 575,662. Moleculin Biotech has a 12 month low of $0.16 and a 12 month high of $15.75. The stock has a market capitalization of $4.15 million, a price-to-earnings ratio of -0.03 and a beta of 1.84. The business’s 50 day simple moving average is $1.95 and its two-hundred day simple moving average is $2.43.

Moleculin Biotech (NASDAQ:MBRX) last issued its earnings results on Thursday, August 13th. The company reported ($1.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.55) by $0.15. Equities analysts forecast that Moleculin Biotech will post -3.08 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Wall Street Zen upgraded shares of Moleculin Biotech from a “strong sell” rating to a “sell” rating in a report on Saturday. Weiss Ratings reissued a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Friday, July 17th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Moleculin Biotech currently has an average rating of “Hold” and an average price target of $22.00.

Hedge Funds Weigh In On Moleculin Biotech

An institutional investor recently bought a new stake in Moleculin Biotech stock. Jane Street Group LLC purchased a new stake in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned approximately 1.11% of Moleculin Biotech as of its most recent filing with the Securities & Exchange Commission. 15.52% of the stock is owned by institutional investors.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.